恩替卡韦分散片治疗HBeAg阳性慢性乙型肝炎的疗效观察  

Clinical effect of entecavir dispersible tablets on treatment of HBeAg-positive chronic hepatitis B

作　　者：赖玺杰[1] 杨益大[1] 郑临[1] 贾红宇[1] 姜秀浓[2] 

机构地区：[1]浙江大学医学院附属第一医院感染科,浙江杭州310003 [2]宁波市第二医院肝病科,浙江宁波315000

出　　处：《中华医院感染学杂志》2016年第5期988-990,共3页Chinese Journal of Nosocomiology

基　　金：浙江省医药卫生计划基金资助项目(2013KYA197)

摘　　要：目的研究恩替卡韦分散片治疗HBeAg阳性慢性乙型肝炎患者的临床治疗效果,为提高治疗效果提供参考。方法选取2013年1月-2015年1月医院诊治的50例HBeAg阳性慢性乙型肝炎患者资料进行分析,采用随机对照方法将患者分为对照组和试验组,每组各25例;对照组采用阿德福韦酯治疗,试验组采用恩替卡韦分散片治疗,比较两组疗效,采用SPSS18.0软件对数据进行统计分析。结果试验组治疗总有效率为92.0%,显著高于对照组的76.0%(P<0.05);两组治疗前谷丙转氨酶(ALT)、谷草转氨酶(AST)、白蛋白/球蛋白比值(A/G)及总胆红素(TBIL)指标差异无统计学意义;试验组患者治疗后ALT、AST等指标显著低于对照组(P<0.05);试验组治疗后A/G及TBIL指标,显著高于对照组(P<0.05);试验组HBV-DNA、HBeAg转阴率及HBeAg/抗HBe转换率,显著高于对照组,差异有统计学意义(P<0.05)。结论 HBeAg阳性慢性乙型肝炎患者采用恩替卡韦分散片治疗效果理想,能够提高临床疗效,改善患者肝功能。OBJECTIVE To observe the clinical effect of entecavir dispersible tablets on treatment of the patients with HBeAg-positive chronic hepatitis B so as to improve the clinical therapeutic effect.METHODS The data were collected from 50 patients with HBeAg-positive chronic hepatitis B who were treated in hospitals from Jan 2013 to Jan 2015,the enrolled patients were randomly divided into the control group and the experimental group,with 25 cases in each.The control group was treated with adefovir dipivoxil,while the experimental group was treated with entecavir dispersible tablets.The clinical therapeutic effect was observed and compared between the two groups of patients,and the statistical analysis of data was performed with the use of SPSS18.0software.RESULTS The total effective rate of treatment of the experimental group was 92.0%,significantly higher than 76.0% of the control group（P〈0.05）.There was no significant difference in the level of alanine aminotransferase（ALT）,aspartate aminotransferase（AST）,total bilirubin（TBIL）,or ratio of albumin to globulin between the two groups before the treatment;the levels of ALT and AST of the experimental group were significantly lower than those of the control group after the treatment（P〈0.05）.The ratio of A/G and level of TBIL of the experimental group were significantly higher than those of the control group（P〈0.05）.The negative rates of HBV-DNA and HBeAg and the conversion rate of HBeAg/anti-HBe were significantly higher in the experimental group than in the control group（P〈0.05）.CONCLUSION The entecavir dispersible tablets can achieve ideal effect on treatment of the HBeAg-positive chronic hepatitis B patients,raise the clinical effect,and improve the liver function of the patients.

关 键 词：HBEAG阳性 慢性乙型肝炎 感染 恩替卡韦分散片 治疗效果 

分 类 号：R512.62[医药卫生—内科学]